Romeo R. Dizon, the Chief Financial Officer of Iridex Corp (NASDAQ:IRIX), bought 3,385 shares of the company's common stock on January 27, 2026. The shares were acquired at $1.4799 apiece, for a total outlay of approximately $5,009. After completing the purchase, Dizon directly holds 110,289 shares of Iridex.
Company financial update
Iridex released preliminary unaudited results for the fourth quarter indicating revenue in a range between $14.6 million and $14.8 million. The company said this represents an increase of 15% to 17% compared with the same quarter a year earlier. Iridex also reported achieving positive cash flow in the fourth quarter and stated an expectation to post positive adjusted EBITDA for the full year 2025.
Those figures follow a less favorable third-quarter 2025 report in which Iridex recorded a net loss of $1.6 million and revenue of $12.5 million, a level below the analyst consensus of $13.1 million.
Clinical evidence and product development
In a separate development, an independent study published in the journal Ophthalmology and Therapy evaluated Iridex's MicroPulse transscleral laser approach for glaucoma retreatment. The study found the technology to be effective, reporting a significant reduction in intraocular pressure among treated patients. The company noted this research as part of ongoing attention to its technological progress in the medical community.
Context and investor focus
Investors and analysts have monitored these mixed indicators closely. The recent preliminary Q4 revenue growth and the reported positive cash flow are potential signals of operational improvement following the Q3 shortfall. At the same time, prior quarterly losses and missed revenue expectations remain part of the company's near-term record.
Iridex's advances in clinical research and its reported financial trajectory are likely to remain focal points for market participants assessing the company's performance and prospects.